Anupam Rasayan India Ltd - Q1 FY27 Earnings Call Summary Friday, 14 August 2026, 2:00 PM IST
Event Participants
Executives
4 Amit Khurana, Anand Desai, Gopal Agrawal, Vishal Thakkar
Analysts
11 Ankur Kumar, Darshil Jhaveri, Hardik Solanki, Josh, Meet Vora, Nishant Batra, Probal Sen, Saurabh Gupta, Sujal, Tanya Chowdhary, Vedant
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Income | ₹667.5 crores | +36% YoY vs ₹490.7 crores; driven by new product commercialization and Jayhawk consolidation |
| Revenue from Operations | ₹655 crores | Strong start to FY27 with continued demand across key segments |
| EBITDA | ₹174.9 crores | +35% YoY vs ₹129.2 crores; margins stable at 26% |
| EBITDA Margin | 26% | Broadly stable YoY; standalone guidance 24-26%, consolidated 22-24% |
| PAT | ₹51.2 crores | +6% YoY vs ₹48.5 crores; PAT margin ~8%; lower growth due to higher depreciation from Jayhawk |
| Cash Profit | ₹64 crores | Compared to ₹56 crores in Q1 FY26 |
| PBT | ₹69.7 crores | vs ₹62.9 crores in Q1 FY26 |
| Jayhawk Revenue Contribution | ~₹145 crores (20-22% of total) | EBITDA margin 19-20%; PAT ₹8-10 crores due to high depreciation |
| Jayhawk EBITDA | ~₹30 crores | 19-20% margin on ~₹145 crore revenue |
| Organic Revenue Growth (ex-Jayhawk) | Single digit | Q1 seasonally tepid; full year guided 20-25% growth |
Geographic & Segment Commentary
Agrochemicals: Demand recovery is visible with robust demand for current products. Management expects agri contribution to remain stable but decline as a percentage of mix, not due to slowing agri business but because pharma and performance materials are growing faster. Forecasts made at start of year are on track.
Pharmaceuticals: One new pharma product commercialized during the quarter. Pipeline includes 65+ pharma and polymer molecules in R&D/pilot stages, with 10+ molecules commercialized over last two years. GVS Pharma acquisition progressing; expected to close by first half of September 2026. GVS platform has 62-molecule pipeline over next 2 years, including 48+ molecules for emerging markets.
Performance Materials: Two new products commercialized during the quarter. Polymer business expected to reach 20-25% of standalone revenue and 30-35% of consolidated revenue. ETFE (ethyl trifluoroacetate) commercialized using flow chemistry - first company globally to commercialize EPFH-based technology. Semicon business growing rapidly with strong traction from existing and new customers, accelerated by Jayhawk's validated semiconductor portfolio.
Jayhawk Fine Chemicals (US): Contributed 20-22% of consolidated revenue (~₹145 crores) with robust 19-20% EBITDA margins. FY27 is first full year of contribution and integration. Completely unlevered with no CapEx support required from Anupam. Semiconductor and performance material products are key end-market exposures; Bain & Co. engaged for PMO/IMO to assess and realize synergies.
Company-Specific & Strategic Commentary
Flow Chemistry Leadership: Commercialized ETFE using flow chemistry - globally first for EPFH-based technology. Provides improved process control, safety, scalability, and cost efficiency. Estimated total addressable market of ~US$500 million for this molecule.
Basfalt LOI: Signed letter of intent for potential long-term supply worth ~US$300 million over 10 years. Technology fully developed at lab and pilot scale; commercialization expected in H2 FY27 with meaningful revenue ramp in 2-3 years.
Cumulative LOI Pipeline: Combined signed LOIs represent ~₹18,000 crores of potential business over respective 10-year periods, with several new products scheduled for commercialization from FY27 onwards.
Acquisition Strategy: Multi-pronged platform approach - Tanfac for backward integration, Anupam for custom synthesis, Jayhawk for US manufacturing/CDMO, and Bliss GVS for pharmaceutical formulations. Bliss acquisition funded with ~₹300 crores debt plus equity-linked instrument; asset-light approach to future API acquisition using Bliss's strong cash flows.
Capital Allocation: Major CapEx cycle completed; all planned projects commissioned and operational. Going forward, only ₹70-80 crores annual CapEx for maintenance, repair, and repurposing. Selective incremental investments based on customer visibility and returns.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (FY27) | 20-25% organic + 10-15% from Jayhawk | Organic growth plus Jayhawk addition (not in base) |
| EBITDA Margins | 24-26% standalone; 22-24% consolidated | Multiple segments/end markets; stable trajectory |
| Polymer Share | 20-25% standalone; 30-35% consolidated | Increasing contribution from performance materials |
| CapEx (FY27) | ₹70-80 crores | Maintenance and repurposing only; major cycle complete |
| Interest Cost | Similar to current run rate | No significant increase expected |
| GVS Acquisition Close | First half of September 2026 | SEBI approval received; open offer concluded August 10th |
| GVS Capacity Utilization | 30% → 60-70% over 2-3 years | Confidence strengthening based on recent performance |
| Basfalt LOI Commercialization | H2 FY27 commencement; full ramp in 2-3 years | US$300 million over 10 years |
| Working Capital | Improvement expected in FY27 | Stable in Q1; better inventory and receivable management with mix shift |
Risks & Constraints
| Risk | Context |
|---|---|
| PAT Growth Disconnect | EBITDA growing 35% but PAT only 6% due to increased depreciation (Jayhawk) and interest costs. Management confirmed no major capitalization going forward and interest at run-rate, but PAT accretion remains a watch item until full integration benefits materialize. |
| GVS Acquisition Execution | Transaction expected to close by mid-September 2026; only minimal shares tendered in open offer. Integration planning, synergistic execution (especially CDMO and cross-selling), and achieving 60-70% utilization target remain execution risks. |
| Agrochemical Segment Softness | Q1 seasonally tepid; demand recovery visible but contribution will decline as percentage of mix. Any agro demand downturn would impact growth since agro remains a significant part of the portfolio. |
| New Product Ramp Timelines | Basfalt LOI and ETFE commercialization require 2-3 years for meaningful revenue contribution. Semiconductor products still in validation phase at Anupam; delays in customer approvals could defer revenue. |
| Regulatory Approvals (Tanfac) | Q&A discussion on Tanfac SCC quota referenced management confidence and belief in Tanfac's guidance; no specifics provided on timeline, leaving regulatory approval risk open. |
Q&A Highlights
GVS Pharma Acquisition Status & Funding
- Question: What is the acquisition timeline and pending approvals? Also asking about funding structure. (Tanya Chowdhary, Investec; Josh, Individual Investor)
- Answer: SEBI approval received; open offer concluded on August 10th with very few shares tendered (insignificant number), reflecting shareholder confidence. Transaction expected to fully close by first half of September 2026. Funding via ~₹300 crores debt in a wholly-owned subsidiary plus balance through equity-linked instrument with Anupam having buyout right. (Vishal Thakkar)
Jayhawk Contribution & Margins
- Question: What was Jayhawk's revenue contribution, EBITDA margin, and PAT? (Hardik Solanki, ICICI Securities; Tanya Chowdhary, Investec)
- Answer: Jayhawk contributed ~₹145 crores revenue (20-22% of total), EBITDA of ~₹30 crores (19-20% margin), and PAT of ₹8-10 crores. Higher depreciation due to legacy depreciation periods from old management, not new CapEx. Jayhawk is completely unlevered and self-funded for any CapEx requirements. (Vishal Thakkar)
ETFE Flow Chemistry Opportunity
- Question: How significant is the ETFE flow chemistry commercialization? What is the market size and margin profile? (Meet Vora, JM Financial)
- Answer: Flow chemistry is cutting-edge technology used commercially by very few globally. Benefits include improved safety, higher quality, lower environmental footprint, and smaller plant footprint. ETFE has applications across pharma, agro, electronics, and semiconductors. Market size estimated at ~US$500 million. Anupam targeting 5-10% initially, up to 15-30% over time. Cost parameters will be better, providing upward bias to margins given CDMO value creation. (Vishal Thakkar)
Basfalt LOI & Order Book Ramp
- Question: Where is the Basfalt LOI in terms of ramp-up and technology readiness? How does order book execution look? (Harsh Shah, Axis Capital)
- Answer: Technology is fully developed at lab and pilot scale; LOI signed only because capability was proven. Commercialization expected in H2 FY27 with meaningful revenue in 2-3 years. Order book contributed ~₹400+ crores revenue last year; this year expecting ~25% of revenue from order book, growing to ~30% going forward. Most products commercialized or to be commercialized this year. (Vishal Thakkar)
Agri Business Outlook
- Question: What is the outlook for the agri segment over the next 12-18 months? (Probal Sen, ICICI Securities)
- Answer: Demand recovery is visible with robust demand for existing products. Forecasts made at the start of the year are on track. Agri contribution will decline as percentage only because pharma and performance materials are growing faster; agri itself should be stable with its own growth path. (Vishal Thakkar)
GVS CDMO & API Acquisition Plans
- Question: Is there a plan to acquire an API company, and what is the funding for it? How is CDMO progressing at GVS? (Saurabh Gupta, Financially Free; Ankur Kumar, Alpha Capital)
- Answer: API facility access is planned; will sit with GVS management post-consummation to decide on asset type, timing, and location. GVS has over ₹200 crores cash flow, no debt, strong receivables - internal accruals sufficient; no large external capital needed. CDMO discussions will follow same approach as Jayhawk - joint offerings post-integration. GVS performance this quarter was fully organic. (Vishal Thakkar)
Semiconductor Progress
- Question: What is the progress on the semicon chemicals business? (Meet Vora, JM Financial)
- Answer: Semicon is growing very fast with strong traction from existing and new customers. Jayhawk has a well-validated portfolio for semiconductor industry; combining with Anupam's products creates a strong growth factor. Anupam is in the process of getting commercial validation on its semicon products. Jayhawk's reasonable revenue share already comes from semicon end-market. (Vishal Thakkar)
Tanfac SCC 32 Quota
- Question: Where is the SCC 32 quota in terms of paperwork and formal approval? (Probal Sen, ICICI Securities)
- Answer: Deferred to Tanfac management's guidance on their call. Anupam remains confident in Tanfac management's estimates and plans, with complete belief in their guidance. (Vishal Thakkar)
Key Takeaway
Anupam Rasayan delivered a strong start to FY27 with consolidated total income of ₹667.5 crores (+36% YoY), EBITDA of ₹174.9 crores (+35% YoY, 26% margin), and PAT of ₹51.2 crores (+6% YoY), with PAT growth constrained by Jayhawk's higher depreciation. The quarter marked key strategic milestones: commercializing ETFE using flow chemistry (first globally), signing a US$300 million LOI with Basfalt, and progressing the GVS Pharma acquisition toward September 2026 closure. Jayhawk contributed 20-22% of revenue at 19-20% EBITDA margins, now in its first full integration year with Bain & Co. driving synergy realization. The company's cumulative LOI pipeline stands at ~₹18,000 crores over 10 years, with order book expected to contribute ~25% of revenue in FY27. Management guided 20-25% organic revenue growth plus 10-15% from Jayhawk, with polymer business scaling to 30-35% of consolidated revenue. With major CapEx cycle complete (₹70-80 crores annual maintenance CapEx only), focus shifts to working capital improvement, achieving 60-70% utilization at GVS over 2-3 years, and progressing semicon/performance materials validation. Key watch points include PAT accretion as depreciation normalizes, GVS integration execution post-September, and agro demand trajectory through FY27.